Attached files

file filename
EX-10.5 - EX-10.5 - Wave Life Sciences Ltd.wve-ex105_181.htm
EX-32.1 - EX-32.1 - Wave Life Sciences Ltd.wve-ex321_7.htm
EX-31.2 - EX-31.2 - Wave Life Sciences Ltd.wve-ex312_8.htm
EX-31.1 - EX-31.1 - Wave Life Sciences Ltd.wve-ex311_9.htm
EX-10.4 - EX-10.4 - Wave Life Sciences Ltd.wve-ex104_180.htm
EX-10.3 - EX-10.3 - Wave Life Sciences Ltd.wve-ex103_179.htm
EX-10.2 - EX-10.2 - Wave Life Sciences Ltd.wve-ex102_178.htm
EX-10.1 - EX-10.1 - Wave Life Sciences Ltd.wve-ex101_177.htm
10-Q - 10-Q - Wave Life Sciences Ltd.wve-10q_20160930.htm

 

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of WAVE LIFE SCIENCES LTD. (the “Company”) on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Keith C. Regnante, Chief Financial Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 9, 2016

 

By:

 

/s/ Keith C. Regnante

 

 

Keith C. Regnante

 

 

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of WAVE Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.